FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer

Hematology / oncology news burst

Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news